Report
Martial Descoutures

Roche Holding : Q3 still weak but full-year guidance maintained

>Q3 2020 sales up 1% at constant currency - Roche reported disappointing Q3 sales, 4% below the consensus expectations (FactSet), up 1% at constant currency (cc) but marked as expected by a highly negative currency effect (-7%). In detail, the historic franchise (Avastin, MabThera and Herceptin) remain penalised by competition from biosimilars (declines of 30-38% cc) and disappointed the consensus. Even Actemra, which continues to benefit from COVID-19 sales over the ...
Underlying
Roche Holding Ltd

Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch